December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Globus Medical, Inc. Class A Common Stock (NY:GMED)

80.31 +2.36 (+3.02%)
Streaming Delayed Price Updated: 10:32 AM EDT, Jun 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Globus Medical, Inc. Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
News headline image
Globus Medical Inc (NYSE:GMED) Stock Surges on Strong Q3 2025 Earnings Beat and Raised Guidance ↗
Globus Medical's Q3 2025 earnings crushed estimates, with EPS of $1.18 beating by 47%. The stock surged over 22% as the company also raised its full-year profit guidance. 
Via Chartmill
Topics Earnings
News headline image
Globus Medical’s (NYSE:GMED) Q3: Strong Sales, Stock Jumps 19.2%
Medical device company Globus Medical (NYSE:GMED) announced better-than-expected revenue in Q3 CY2025, with sales up 22.9% year on year to $769 million. The company’s full-year revenue guidance of... 
Via StockStory
News headline image
What's going on in today's after hours session ↗
Discover the top movers in Thursday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
News headline image
Globus Medical Reports Third Quarter 2025 Results
From Globus Medical
Via GlobeNewswire
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
A Preview Of Globus Medical's Earnings ↗
 
Via Benzinga
News headline image
Globus Medical (GMED) Q3 Earnings: What To Expect
Medical device company Globus Medical (NYSE:GMED) will be reporting results this Thursday after market hours. Here’s what investors should know. 
Via StockStory
News headline image
2 Growth Stocks with All-Star Potential and 1 We Find Risky
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who... 
Via StockStory
Topics Electric Vehicles
News headline image
Paradice Dumped Its Entire $15.2 Million Progressive Software Stake ↗
Paradice Dumped Its Entire $15.2 Million Progressive Software Stake 
Via The Motley Fool
News headline image
Globus Medical Schedules Third Quarter Earnings Release and Conference Call
From Globus Medical
Via GlobeNewswire
News headline image
Globus Medical Launches ANTHEM™ Elbow Fracture System: A Comprehensive Plating Portfolio for Complex Elbow Trauma
From Globus Medical
Via GlobeNewswire
News headline image
Myriad Genetics, Omnicell, Globus Medical, Repligen, and Teleflex Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump. 
Via StockStory
Topics Economy Government World Trade
News headline image
Winners And Losers Of Q2: Globus Medical (NYSE:GMED) Vs The Rest Of The Medical Devices & Supplies - Specialty Stocks
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - specialty industry, including Globus Medical (NYSE:GMED) and its peers. 
Via StockStory
News headline image
3 Cash-Producing Stocks Worth Your Attention
Businesses with strong free cash flow tend to be more adaptable and resilient. Some of these companies shine bright by using their cash wisely to strengthen their market positions. 
Via StockStory
News headline image
1 Cash-Heavy Stock with Exciting Potential and 2 That Underwhelm
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining... 
Via StockStory
News headline image
2 Reasons to Watch GMED and 1 to Stay Cautious
Globus Medical’s stock price has taken a beating over the past six months, shedding 21.5% of its value and falling to $57.60 per share. This may have investors wondering how to approach the situation. 
Via StockStory
Topics Government World Trade
News headline image
Growth Titans: Eli Lilly's Weight-Loss Surge vs. Johnson & Johnson's Diversified Might
The pharmaceutical landscape is currently a tale of two giants employing vastly different, yet highly successful, growth strategies. Eli Lilly and Company (NYSE: LLY) has placed an extraordinary bet on... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
2 of Wall Street’s Favorite Stocks with Promising Prospects and 1 We Question
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because... 
Via StockStory
News headline image
1 Small-Cap Stock with Solid Fundamentals and 2 Facing Headwinds
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a... 
Via StockStory
News headline image
Globus Medical, Inc. Secures Jury Verdict in Delaware Patent Litigation Against Life Spine, Inc.
From Globus Medical
Via GlobeNewswire
News headline image
Sherwin-Williams, Sealed Air, Super Micro, Globus Medical, and Haemonetics Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after the major indices rebounded, as Fed Chair Jerome Powell delivered dovish remarks at the much-awaited Jackson Hole symposium. Powell suggested... 
Via StockStory
Topics ETFs Economy
News headline image
Carlsmed's Personalized Spine Implants Get Significant Reimbursement Advantage ↗
Carlsmed secures NTAP reimbursement and FDA support, while BofA projects strong revenue growth and assigns a Buy rating with a $16 target. 
Via Benzinga
News headline image
Globus Medical Inc - A (NYSE:GMED): A Prime Example of Affordable Growth with Strong Fundamentals ↗
Globus Medical (GMED) exemplifies Affordable Growth investing with strong revenue/earnings growth, reasonable valuation, and solid profitability—ideal for GARP-focused investors. 
Via Chartmill
News headline image
1 Cash-Producing Stock Worth Your Attention and 2 We Find Risky
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. 
Via StockStory
News headline image
Inspire Medical Systems, UFP Technologies, Globus Medical, Neogen, and Dentsply Sirona Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. 
Via StockStory
Topics Bonds Economy Stocks
News headline image
GMED Q2 Deep Dive: New CEO, Nevro Integration, and Product Pipeline Propel Growth
Medical device company Globus Medical (NYSE:GMED) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 18.4% year on year to $745.3 million. The company expects the full... 
Via StockStory
Topics Economy
News headline image
Globus Medical (GMED) Shares Skyrocket, What You Need To Know
Shares of medical device company Globus Medical (NYSE:GMED) jumped 5.1% in the morning session after the company reported strong second-quarter financial results that surpassed Wall Street's... 
Via StockStory
News headline image
Globus Medical (NYSE:GMED) Exceeds Q2 Expectations
Medical device company Globus Medical (NYSE:GMED) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 18.4% year on year to $745.3 million. The company expects the full year’s revenue... 
Via StockStory
News headline image
Globus Medical (GMED) Q2 Revenue Up 18% ↗
Via The Motley Fool
News headline image
Globus Medical Reports Second Quarter 2025 Results
From Globus Medical
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.